Placenta Lab, Department of Obstetrics, Jena University Hospital, 07747, Jena, Germany; Department of Maternal-Fetal Medicine, Institute Clínic of Gynecology, Obstetrics and Neonatology (ICGON), Hospital Clinic-IDIBAPS, University of Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), 08028, Barcelona, Spain
Auto-generated profile, based on publicly available information
Aleida Susana Castellanos Gutierrez
Placenta Lab, Department of Obstetrics, Jena University Hospital, 07747, Jena, Germany; Department of Maternal-Fetal Medicine, Institute Clínic of Gynecology, Obstetrics and Neonatology (ICGON), Hospital Clinic-IDIBAPS, University of Barcelona and Centre for Biomedical Research on Rare Diseases (CIBER-ER), 08028, Barcelona, Spain
A prospectively study of pregnant women with systemic lupus erythematosus (SLE), antiphospholipid syndrome, or non-criteria obstetric antiphospholipid syndrome was conducted to describe the characteristics of women followed in a referral unit and to derive a predictive tool for adverse pregnancy outcome (APO). Demographic characteristics, treatments, SLE activity, and flares were recorded. Laboratory data included a complete blood cell count, protein-to-creatinine urinary ratio (Pr/Cr ratio), complement, anti dsDNA, anti-SSA/Ro, anti-SSB/La, and antiphospholipid antibodies status. A stepwise regression was used to identify baseline characteristics available before pregnancy and during the 1st trimester that were most predictive of APO and to create the predictive model. A total of 217 pregnancies were included. One or more APO occurred in 45 (20.7%) women. A baseline model including non-Caucasian ethnicity (OR 2.78; 95% CI [1.16–6.62]), smoking (OR 4.43; 95% CI [1.74–11.29]), pregestational hypertension (OR 16.13; 95% CI [4.06–64.02]), and pregestational corticosteroids treatment OR 2.98; 95% CI [1.30–6.87]) yielded an AUC of 0.78 (95% CI, [0.70–0.86]). Among first-trimester parameters, only Pr/Cr ratio improved the model fit, but the predictive performance was not significantly improved (AUC of 0.78 vs. 0.81; p = 0.16). Better biomarkers need to be developed to efficiently stratify pregnant women with the most common autoimmune diseases.
1 January 2024 in Clinical & Translational Immunology
Objectives: Antiphospholipid syndrome (APS) is an autoimmune disease driven by antiphospholipid antibodies (aPL). Currently, APS diagnosis requires a combination of clinical manifestations (thrombosis and/or obstetric morbidity) and the persistent presence of at least one criteria aPL: anti‐cardiolipin antibodies (aCL), anti‐β2‐glycoprotein I antibodies (aβ2GPI) or lupus anticoagulant (LA). Patients with suggestive obstetric symptoms but lacking criteria aPL face diagnostic challenges. Non‐criteria aPL screening may enhance discrimination. This study proposes a classification incorporating both criteria and non‐criteria antibodies to improve obstetric APS diagnosis.Methods: Blood samples from non‐pregnant women (n = 68) with a history of vascular, obstetric, or vascular and obstetric manifestations were analysed. Among them, 30 had previous diagnosis of APS. Healthy women with proven gestational success were included as controls (n = 16). Criteria and non‐criteria (anti‐phosphatidylglycerol, anti‐phosphatidylethanolamine, anti‐phosphatidylinositol, anti‐phosphatidylserine and anti‐phosphatidic acid) IgG aPL were evaluated by ELISA and coagulation tests. Based on the resulting aPL profile, patients were reclassified. Responsiveness to treatment was obtained from medical records.Results: Criteria aPL levels marginally differentiated women previously managed as obstetric APS from unexplained/other causes of obstetric morbidity. Including non‐criteria aPL improved separation. The proposed classification identified an obstetric APS group that exhibits non‐criteria aPL and aβ2GPI titres below the cut‐off but higher than healthy women (7.88 vs. 2.47 SGU, P = 0.006). Compared to cases of other causes of obstetric morbidity, these patients retrospectively responded better to aspirin and/or heparin treatment (71.43% vs. 11.11%, P = 0.035).Conclusions: Assessing non‐criteria antibodies may identify isolated obstetric APS cases benefiting from established therapies.
17 March 2022 in Archives of Gynecology and Obstetrics
Objective: To compare the fetal brain structures assessed in routine sonographic scans during the second and third trimesters in fetuses with and without congenital heart disease (CHD). Methods: This is a retrospective cross-sectional single-center study. We measured the head circumference (HC), the transversal diameter of the cerebellum (TCD) and the sizes of the cisterna magna (CM), the cavum septi pellucidi (CSP) and the posterior ventricles (PV) between 20 and 41 weeks of gestation. We compared 160 fetuses with CHD (case group) to 160 fetuses of normal pregnancies (control group). Every patient was matched with a control, considering the gestational age at which the ultrasound was performed. We divided the CHD group into 3 subgroups: retrograde flow in the aortic arch (group 1), right heart anomaly with the antegrade flow in the aortic arch (group 2) and other CHDs with the antegrade flow in the aortic arch (group 3). Results: The mean width of the PV was larger in fetuses of groups 1 and 3 in comparison to the control group (P < 0.001, P = 0.022; respectively). We found that the APGAR score at 5 min (P < 0.001, P < 0.001; respectively) and gestational age at delivery (P = 0.006, P = 0.001; respectively) were inferior in groups 1 and 3 compared to controls. Conclusions: Central nervous system biometry is altered in fetuses with CHD. PV is enlarged in CHD fetuses especially with decreased oxygen levels in the aortic arch.
Autoimmune diseases (AID) such as systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) or non-criteria-obstetric antiphospholipid syndrome (NC-OAPS) increase the risk of adverse perinatal outcomes (APO). During pregnancy the deregulation of the complement system and the angiogenic factors cause damage to the placenta, resulting in the development of APO. The aim is to evaluate the placental expression of complement proteins, Annexin V (ANNV) and angiogenic factors in patients diagnosed with AID and compare it with healthy controls and fetal growth restricted (FGR) cases. Placental samples were classified into: AID with (13) and without (9) APO, FGR without AID (13), and healthy control group (13). Tissue sections were stained using antibodies against human complement proteins and ANNV. Results were expressed as mean-of-fluorescence-intensity (MFI) values. Total RNA was extracted from paraffin sections and mRNA expression of the angiogenesis-related factors was evaluated by qPCR and normalized using the 2-ΔCt method relative to GAPDH. Lower expression of ANNV in AID + APO (p = 0.028), and AID (p = 0.034) compared to the control. Higher levels of C5b-9 (p = 0.0005 AID + APO and p < 0.0001 AID) C3b (p < 0.0001 both AID groups) and C4d (p < 0.0001 both AID groups and p = 0.0006 in FGR) were found compared to the control group. PlGF expression showed significant increase in the AID group without APO compared to the control group. Excessive complement activation and placental deposition while reduced ANNV is present in SLE, APS and NC-OAPS patients. Elevated PlGF placental expression is a feature of patients with AID without APO.
30 September 2019 in Ultrasound in Obstetrics & Gynecology